Related Experiment Video
Updated: May 15, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
Novel processes to obtain pneumococcal surface proteins for vaccines
1Laboratory of Vaccine Development, Instituto Butantan, Av Vital Brasil 1500, 05503-900, Sao Paulo, Brazil. viviane.goncalves@butantan.gov.br.
Developing serotype-independent pneumococcal vaccines requires early bioprocess development. This review explores protein production, purification, and bioreactor strategies essential for advancing novel pneumococcal protein vaccines.
Area of Science:
- Biotechnology
- Vaccine Development
- Protein Engineering
Background:
- Current pneumococcal vaccines target limited serotypes using polysaccharides.
- Serotype-independent vaccines utilizing pneumococcal surface proteins are under development.
- Limited literature exists on the bioprocess development for these novel protein-based vaccines.
Purpose of the Study:
- To review production and purification processes for pneumococcal surface proteins.
- To discuss bioreactor cultivation strategies for vaccine candidate production.
- To explore purification process features and their correlation with protein structure.
Main Methods:
- Review of existing literature on bioprocess development for pneumococcal protein vaccines.
- Discussion of bioreactor cultivation techniques and their impact on protein production.
- Analysis of purification strategies, including chromatography, based on protein structural features.
Main Results:
- Early bioprocess development is critical for generating sufficient material for testing and characterization.
- Bioreactor cultivation aids in identifying potential process bottlenecks and optimizing production.
- Understanding protein structure-structure relationships can guide the development of effective purification processes.
Conclusions:
- Bioprocess development is essential for the successful scale-up and clinical advancement of pneumococcal protein vaccines.
- Early consideration of industrial-scale production and GMP transfer is vital.
- Integrating protein structure insights into purification strategies can enhance process efficiency and vaccine quality.
More Related Videos
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
00:10Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019